News

AETIONOMY clinical study recruitment reaches milestone of 200 patients recruited

AETIONOMY an IMI funded project, has now recruited over 200 people into the Parkinson’s Disease portion of the European clinical study on neurodegenerative diseases such as Parkinson’s  and Alzheimer’s diseases. This milestone means that the project is 50% completed in both the AD and the PD portion. The Alzheimer’s disease portion is being recruited via EPAD* which has now recruited a total of 123 subjects of which 58 were recruited at the joint center BBRC.

Within the project, patients with neurodegenerative diseases and healthy people are providing blood and cerebrospinal samples to undergo detailed molecular analysis at leading European laboratories. The purpose of  AETIONOMY is to propose novel patient classification based on mechanism-based taxonomies, for both PD and AD.  ‘The AETIONOMY study will allow us to validate in real patients two hypotheses for PD and for AD,’ explains the study coordinator Prof. Jean Christophe Corvol of ICM, Paris. ‘This will then allow clinicians to stratify patients according to biological mechanisms of the disease and potentially to target specific sub-population for drug development.’

2017

  • Feb 2017 We are currently finalizing the Annual Report to IMI for the 2016 period and starting rehearsals for the upcoming Interim Review to be held at the Commission on the 21st March 2017.

  • Jan 2017 WP3 Meeting on "candidate mechanisms by in silico approaches and validation strategies" at Fraunhofer.

  • Jan 2017 Kick off meeting of the Work package 2 activity “The Virtual Dementia Cohort” at Fraunhofer. Ultimately, all clinical studies are just data. For many of the variables measured for example in ADNI and PPMI we actually know the distribution of values; for other variables we may quantify our a priori knowledge. The data may be introduced into forward modeling approaches (integrative cause-and-effect modeling informed by biology) and linked to generative brain network models (The Virtual Brain) to create individual Virtual Patient brain models. We will generate a prototype of a virtual patient cohort.

  • Jan 2017 Start of an academic collaboration with Univ. Oxford (Prof. Simon Lovestone’s group) on the "Analysis of large patient data sets based with text mining".

     

2016

  • 1st Dec 2016 The AETIONOMY consortium held its 3rd General Assembly in Paris at the partners site of Sanofi. The external Scientific Advisory Board members convened and our two new partners, AMU and BBRC, were also present. It was a great chance to provide an update on the current progress that the Consortium has made. The presentations focussing mainly on the „identification of candidate mechanisms and validation strategies" and “annual plans for 2017”. The proposed candidate mechanisms have now been chosen from both the clinical experts (WP5) and the data mining activities (WP3) for both AD and PD. Now comes the challenge to validate those mechanisms in the prospective cohorts and across other data sets.

  • 21 Nov 2016 AETIONOMY welcomes 2 new partners: Université d’Aix Marseille (Work package 2) and the Barcelona Beta Brain Reseach Center (Work package 5). The Clinical Study continues to recruit PD patients with current recruitment at 185/415. The AD patients are being recruited at our partner site BBRC through the EPAD Consortium. Partner Univ. Clinics Bonn will open their site to AD patients on the 22nd February 2017.

  • 11 Oct 2016 Joint workshop with PRECISESADS: WP4 is organising the third annual meeting of the AETIONOMY Legal and Ethical Advisory Board (LEAB), which will take place in Barcelona in October within the framework of the joint meeting of AETIONOMY and its sister IMI project PRECISESADS. This will also give the LEAB an opportunity to consider related ethical issues and approaches in PRECISESADS.

  • Oct Joint WP3/WP5 Workshop: Select hypotheses and markers for WP5 clinical study, 10 Oct 2016, Barcelona. Goal of the workshop: Need a decision for two AD hypotheses and markers for WP5 clinical study.

  • September 26, 2016 - AETIONOMY has now recruited over 100 people into the Parkinson’s Disease portion of the European clinical study on neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. This milestone means that the project is 25% completed in the PD portion. The Alzheimer’s disease portion is being recruited via EPAD which is now also actively recruiting. Within the project, patients with neurodegenerative diseases and healthy people are providing blood and cerebrospinal samples to undergo detailed molecular analysis at leading European laboratories. The purpose of AETIONOMY is to propose novel patient classification based on mechanism-based taxonomies, for both PD and AD. “The AETIONOMY study will allow us to validate in real patients two hypotheses for PD and for AD,” explains the study coordinator Prof. Jean Christophe Corvol of ICM, Paris. “This will then allow clinicians to stratify patients according to biological mechanisms of the disease and potentially to target specific sub-population for drug development.”